Literature DB >> 26271833

Critical review of current and emerging quantification methods for the development of influenza vaccine candidates.

Aziza P Manceur1, Amine A Kamen2.   

Abstract

Significant improvements in production and purification have been achieved since the first approved influenza vaccines were administered 75 years ago. Global surveillance and fast response have limited the impact of the last pandemic in 2009. In case of another pandemic, vaccines can be generated within three weeks with certain platforms. However, our Achilles heel is at the quantification level. Production of reagents for the quantification of new vaccines using the SRID, the main method formally approved by regulatory bodies, requires two to three months. The impact of such delays can be tragic for vulnerable populations. Therefore, efforts have been directed toward developing alternative quantification methods, which are sensitive, accurate, easy to implement and independent of the availability of specific reagents. The use of newly-developed antibodies against a conserved region of hemagglutinin (HA), a surface protein of influenza, holds great promises as they are able to recognize multiple subtypes of influenza; these new antibodies could be used in immunoassays such as ELISA and slot-blot analysis. HA concentration can also be determined using reversed-phase high performance liquid chromatography (RP-HPLC), which obviates the need for antibodies but still requires a reference standard. The number of viral particles can be evaluated using ion-exchange HPLC and techniques based on flow cytometry principles, but non-viral vesicles have to be taken into account with cellular production platforms. As new production systems are optimized, new quantification methods that are adapted to the type of vaccine produced are required. The nature of these new-generation vaccines might dictate which quantification method to use. In all cases, an alternative method will have to be validated against the current SRID assay. A consensus among the scientific community would have to be reached so that the adoption of new quantification methods would be harmonized between international laboratories.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Keywords:  Alternative potency assays; Hemagglutinin; Influenza vaccines quantification; Pandemic; SRID assay; Universal antibodies; Vaccine release; Viral particle count

Mesh:

Substances:

Year:  2015        PMID: 26271833     DOI: 10.1016/j.vaccine.2015.07.104

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.

Authors:  Maria I Solano; Adrian R Woolfitt; Tracie L Williams; Carrie L Pierce; Larisa V Gubareva; Vasiliy Mishin; John R Barr
Journal:  Anal Chem       Date:  2017-02-21       Impact factor: 6.986

2.  Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza.

Authors:  Aziza P Manceur; Wei Zou; Anne Marcil; Eric Paquet; Christine Gadoury; Bozena Jaentschke; Xuguang Li; Emma Petiot; Yves Durocher; Jason Baardsnes; Manuel Rosa-Calatrava; Sven Ansorge; Amine A Kamen
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 3.  The expanding role of mass spectrometry in the field of vaccine development.

Authors:  Vaneet Kumar Sharma; Ity Sharma; James Glick
Journal:  Mass Spectrom Rev       Date:  2018-05-31       Impact factor: 10.946

4.  Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products.

Authors:  Chia-Chun Lai; Tsai-Chuan Weng; Po-Ling Chen; Yu-Fen Tseng; Chun-Yang Lin; Min-Yuan Chia; Wang-Chou Sung; Min-Shi Lee; Alan Yung-Chih Hu
Journal:  Hum Vaccin Immunother       Date:  2020-03-02       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.